))
Interview with Steven Yatomi-Clarke CEO and Managing Director, Prescient Therapeutics
Manage episode 421240257 series 3551735
Conteúdo fornecido por Chris Titley. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Chris Titley ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Today I chat with Steven Yatomi-Clarke around Prescient Therapeutics.
Steven delves in to the history of the business , the growth of the portfolio and the importance of PTX-100 to the business.
Steven talks about the importance of PTX-100 , the process of design, the testing, how it works and also how meaningful the future results are.
Steven also talks about the timeline of broader advances in medicine, the time, the effort as well as trends in AI.
This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.
9 episódios
Compartilhar
